10-Q: Nuwellis Q3 Loss Widens Amid Strategic Shifts & Capital Raises

Nuwellis, Inc. reported a widened net loss for the nine months ended September 30, 2025, alongside strategic realignments including exiting international operations and terminating a clinical trial, while actively raising capital.

Summary

• Net loss for the nine months ended September 30, 2025, significantly increased to $(15.1) million from $(9.7) million in the prior year.
• Net sales decreased by 8.9% to $5.8 million for the nine months ended September 30, 2025, compared to $6.4 million in the same period last year.
• The company successfully regained compliance with Nasdaq's minimum bid price requirement through a 1-for-42 reverse stock split effective July 3, 2025.
• Nuwellis exited international operations to focus on the U.S. market, accruing $254,000 in contractual exit fees and product repurchase obligations.
• The REVERSE-HF clinical trial was terminated, anticipating savings of approximately $4.0 million over 2.5 years.
• Entered a non-binding Letter of Intent to acquire Rendiatech, Ltd., an Israeli medical device company specializing in real-time urine flow and acute kidney injury monitoring technologies.
• Cash and cash equivalents decreased to $3.1 million as of September 30, 2025, from $5.1 million at December 31, 2024.
• The company raised approximately $5.0 million in gross proceeds from a public offering in June 2025 and $1.9 million in net proceeds from an At The Market (ATM) offering as of September 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern for at least the next twelve months from the filing date.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including widening losses, declining revenue, and a going concern warning. While strategic initiatives and capital raises are underway, the fundamental financial performance remains weak, indicating high risk.

Positives

• Successfully regained compliance with Nasdaq's minimum bid price requirement through a reverse stock split.
• Strategic exit from international operations to focus resources on the higher-growth U.S. market.
• Termination of the REVERSE-HF clinical trial is expected to save approximately $4.0 million over 2.5 years.
• Finalized agreement with KDI Precision Manufacturing to expand manufacturing capabilities and streamline operations, with current assembly employees transitioning to KDI.
• Entered a non-binding Letter of Intent to acquire Rendiatech, Ltd., potentially expanding the technology platform beyond ultrafiltration.
• Net cash used in operating activities slightly decreased to $7.78 million for the nine months ended September 30, 2025, from $8.09 million in the prior year.

Negatives

• Net loss significantly widened to $(15.1) million for the nine months ended September 30, 2025, compared to $(9.7) million in the prior year.
• Net sales decreased by 8.9% for the nine months ended September 30, 2025, and by 6.3% for the three months ended September 30, 2025.
• Gross profit percentage declined to 59.4% for the nine months ended September 30, 2025, from 67.3% in the prior year.
• Cash and cash equivalents decreased by $2.0 million from December 31, 2024, to September 30, 2025.
• Accumulated deficit increased to $313.9 million as of September 30, 2025.
• Operating expenses for the three months ended September 30, 2025, increased by 30% primarily due to increased headcount, compensation, and professional services.
• The company's consolidated financial statements have been prepared on a going concern basis, but factors raise substantial doubt about its ability to continue as a going concern for at least the next twelve months.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern through at least twelve months from the filing date.
• Risk of delisting from Nasdaq if the company fails to maintain compliance with listing requirements, particularly the Stockholders Equity Requirement, for which it is under a Mandatory Panel Monitor.
• Failure to comply with federal and state laws regarding off-label use of products could lead to substantial civil and criminal penalties, adversely affecting business and financial condition.
• Potential adverse impact from changes to U.S. tariff and import/export regulations, especially concerning raw materials sourced from China.
• Disruptions at the FDA and other government agencies (e.g., restructuring, government shutdown) could hinder product review and approval, negatively impacting the business.
• Interruption in supply from material sole source suppliers could harm business operations due to potential inability to obtain adequate alternative quantities or at commercially reasonable prices.
• Inability to raise additional capital on favorable terms or at all, which is necessary to support growth or other strategic initiatives.

Future Outlook

The company expects to incur additional losses in the near-term as it grows the Aquadex Business, investing in sales and marketing, product development, inventory, and clinical evidence. It believes existing capital resources will support operations into the first quarter of 2026 but will seek additional capital through debt, equity, or a combination thereof. The proposed acquisition of Rendiatech, Ltd. aims to expand the technology platform beyond ultrafiltration to include continuous renal health monitoring.

Management Comments

• "We expect to incur additional losses in the near-term as we grow the Aquadex Business, including investments in our sales and marketing capabilities, product development, purchasing inventory components, generating additional clinical evidence supporting the efficacy of the Aquadex System, and complying with the requirements related to being a U.S. public company."
• "To become and remain profitable, we must succeed in expanding the adoption and market acceptance of the Aquadex System."
• "We believe that our existing capital resources will be sufficient to support our operating plan into the first quarter of 2026."
• "We will seek to raise additional capital to support our growth or other strategic initiatives through debt, equity, or a combination thereof."
• "This strategic realignment [exiting international operations] supports Nuwellis core business strategy: investing in the markets driving revenue growth."

Industry Context

Nuwellis operates in the medical technology sector, specifically targeting cardio-renal conditions with its Aquadex SmartFlow system for ultrafiltration. The strategic shift to focus solely on the U.S. market, coupled with the termination of a clinical trial and a potential acquisition in renal health monitoring, indicates a move towards streamlining operations and focusing on high-potential growth areas within its niche. The company's challenges with profitability and capital raising are common for microcap medical device companies in a competitive and capital-intensive industry.

Management Changes

Corporate Governance

Related Party Transactions

• John L. Erb, the company's Chief Executive Officer, exchanged 100 shares of Series F Preferred Stock for Series F-1 Preferred Shares pursuant to a Securities Exchange Agreement dated June 9, 2025.

Stakeholder Impact

• Shareholders face significant dilution from recent capital raises and the reverse stock split, continued risk of delisting, and substantial doubt about the company's ability to continue as a going concern.
• Employees involved in assembly operations transitioned to KDI Precision Manufacturing as part of a strategic outsourcing initiative.
• Customers in the U.S. may benefit from the company's focused strategy, while international customers will be impacted by the exit from selected international operations.
• Creditors face elevated risk due to the company's going concern warning and accumulated deficit.
• Suppliers, particularly sole source providers, remain critical, and any interruption could severely impact the company's ability to manufacture products.

Next Steps

• Expand sales and marketing capabilities for the Aquadex Business.
• Invest in new product development and purchasing inventory components.
• Generate additional clinical evidence supporting the efficacy of the Aquadex System.
• Continue efforts to expand adoption and market acceptance of the Aquadex System.
• Seek additional capital through debt, equity, or a combination thereof.
• Continue discussions and due diligence for the potential acquisition of Rendiatech, Ltd.
• Substantially pay out accrued contractual exit fees and product repurchase obligations for international operations by the end of the first quarter of fiscal 2026.
• Evaluate disclosure approach for ASU 2023-09 and anticipate adopting the standard for the annual period ending December 31, 2025.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial accumulated deficit of $313.9 million, widening net losses, and declining revenue. The explicit 'going concern' warning indicates a high probability of financial instability or failure within the next year. While strategic initiatives like exiting international markets and a potential acquisition are attempts to pivot, they are insufficient to offset the fundamental financial weaknesses. Frequent capital raises, including an ATM offering, suggest ongoing liquidity issues and lead to significant shareholder dilution. Despite resolving a Nasdaq bid price deficiency, the company remains under a 'Mandatory Panel Monitor' for its stockholders' equity, posing a continued delisting risk. The overall financial health and operational trajectory present an extremely high-risk investment profile with a strong likelihood of further value erosion.

Keywords

Nuwellis, NUWE, 10-Q, Quarterly Report, Medical Technology, Aquadex SmartFlow, Ultrafiltration, Cardio-renal, Fluid Overload, Nasdaq Compliance, Reverse Stock Split, Capital Raise, Going Concern, Rendiatech, KDI Precision Manufacturing, Clinical Trial Termination, International Operations Exit, Financial Results